alexa
Reach Us +1 218 451 2974
Early Prevention Of Alzheimer’s Disease: Scientific Justification And Current Strategies | 106502
ISSN: 2155-9562

Journal of Neurology & Neurophysiology
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Early prevention of Alzheimer’s disease: Scientific justification and current strategies

15th International conference on dementia and Alzheimers disease

Karen Ritchie

French National Institute of Medical Research (INSERM), France

ScientificTracks Abstracts: J Neurol Neurophysiol

Abstract
Increasing evidence from longitudinal imaging studies and prospective epidemiological observations suggests that Alzheimer???s pathology is present decades before a dementia diagnosis. What is now referred to as late-onset Alzheimer???s Disease (AD) is thus likely to be a clinically silent disorder of mid-life rather than a disease of old age. This view is further supported by risk factor studies which demonstrate that targeting mid-life exposure to the principal risk factors may significantly reduce dementia incidence. Current evidence suggests that a change in clinical approach notably involving promotion of cardiovascular health in persons with a family history of Alzheimer???s disease may considerably delay dementia onset and also that the development of biomarkers at this early stage will lead to the possibility of pre-clinical trials. Two international intiatives are described; the prevent multi-site Project and the EPAD Clinical Trials Platform which are currently developing new protocols for pre-clinical treatment.
Biography

Karen Ritchie is a Neuropsychologist and Epidemiologist who began her career with the Health Services Evaluation Unit, University of Oxford and the Social Psychiatry Research Unit, MRC Australia. She is currently Director of the French National Institute of Medical Research (INSERM) Neuropsychiatry unit in Montpellier, France. She has also worked as an Advisor to WHO, the French National Institute of Health Surveillance and as an Board Member of the European Institute of Women’s Health. She has over 350 peer-reviewed publications.

E-mail: [email protected]

 

Relevant Topics
Top